4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
The international trade fair “Ideas – Inventions – New Products” iENA celebrated its 75th anniversary in 2023. Over thre…
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T…
ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, today announced that the European Medicines Agency (…
4SC AG (4SC, FSE Prime Standard: VSC) announced that the results from the RESMAIN Study evaluating resminostat (Kinselby…
. The European Medicines Agency (EMA) has notified 4SC that it has accepted its Letter of Intent to Submit a Marketing…
4SC AG (4SC, FSE Prime Standard: VSC) has now filed with EMA its letter of intent to file for Marketing Authorization fo…
Resminostat met the primary endpoint in the RESMAIN study, demonstrating a statistically significant improvement in prog…
How can aging be delayed? Graz-based heart scientist Mahmoud Abdellatif, MD PhD (Doctor of Medicine and Philosophy) has…
NEWARK, Del: The ISO container market is projected to secure a valuation of US$ 266.53 million in 2023 and is expected t…